Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Summit TherapeuticsMEX:SMMT 30 Debt-to-Equity is 0.03 as of Jun. 2026, which is at its 10-year median of 0.03. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 962 Biotechnology companies, Summit Therapeutics ranks better than 81.19% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Summit Therapeutics's Debt-to-Equity or its related term are showing as below:
MEX:SMMT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.41 Med: 0.03 Max: 4.1
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Summit Therapeutics was 4.10. The lowest was -0.41. And the median was 0.03.
MEX:SMMT's Debt-to-Equity is ranked better than 81.19% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs MEX:SMMT: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Summit Therapeutics Debt-to-Equity Related Terms
Summit Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Summit Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SMMT vs TECH, AXSM, KRYS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Summit Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Summit Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Summit Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Summit Therapeutics (MEX:SMMT) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Summit Therapeutics and its competitors. This is near median its historical median of 0.03. According to the industry distribution chart, Summit Therapeutics ranks #181 out of 962 companies in the Biotechnology industry, placing it in the top 18.8%.
Is Summit Therapeutics' Debt-to-Equity too high?
Summit Therapeutics' current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Summit Therapeutics' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Summit Therapeutics ranks #181 out of 962 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Debt-to-Equity compare to TECH and AXSM?
According to the Biotechnology industry distribution chart, Summit Therapeutics ranks #181 out of 962 companies for Debt-to-Equity. This places Summit Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Summit Therapeutics' value of 0.03 is 81.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Summit Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Summit Therapeutics's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Summit Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Summit Therapeutics's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Debt-to-Equity of 0.03. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 81.3% below the Biotechnology industry median of 0.16. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score
Get the complete analysis for MEX:SMMT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SMMT has been successfully added to your 
